Sunil Samnani

Dr. Sunil Samnani

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
SSSunil Samnani
Sunil Samnani
EWEmily C L Wong
Emily C L Wong
HHHasan Hamam
Hasan Hamam
PDParambir S Dulai
Parambir S Dulai
JMJohn K Marshall
John K Marshall
NNNeeraj Narula
Neeraj Narula
Background and Aims: Inflammatory bowel disease (IBD) trials often stratify patients by prior biologic exposure, including prior biologic failure or intolerance. This study aimed to assess clinical outcomes in IBD patients with prior biologic failure vs intolerance treated with ustekinumab or vedolizumab. Methods: A post-hoc analysis of ulcerative colitis (UC) and Crohn’s disease (CD) clinical trials for ustekinumab (UNITI and UNIFI) and vedolizumab (GEMINI-1 and GEMINI-2) was performed. Clinical response, clinical remission, and endoscopic improvement (for UC) were compared among biologic naïve, biologic failure, and biologic intolerant patients. Statistical analyses, including chi-square tests and logistic regression, were performed. Results: A total of 1178 UC and 1439 CD patients received either ustekinumab or vedolizumab. In UC, biologic intolerant patients exhibited higher clinical response (54.7% vs 38.8%, aOR 1.87 [95% CI, 0.93-3.73]), clinical remission (25.0% vs 11.0%, aOR 2.84 [95% CI, 1.47-5.49]), and endoscopic improvement (40.6% vs 24.8%, aOR 2.76 [95% CI, 1.28-5.94]) compared to biologic failure, with outcomes similar to biologic naïve patients. In biologic intolerant CD patients, clinical response was similar between prior biologic failure and intolerance (34.2% vs 32.8%), but after adjustment for potential confounders, biologic intolerance was associated with higher odds of clinical response (aOR: 1.67, 95% CI, 1.09-2.55), with no significant difference observed for clinical remission (aOR: 1.48, 95% CI, 0.88-2.49). Conclusions: Improved treatment outcomes were generally observed in patients with biologic intolerance compared to failure, especially in UC, where outcomes were similar to biologic naïve patients. Future clinical trials should meticulously differentiate prior biologic failure vs intolerance to mitigate potential bias.

11 April 2014 in Indian Journal of Surgery
Verified
Journal Article
Open access
PDF file
SSSunil Samnani
Sunil Samnani
AAAun Ali
Aun Ali
Dear Editor, This correspondence is to discuss an incidental finding identified while conducting laparoscopic cholecystectomy. A 34-year-old female visited the outpatient department of a tertiary hospital of Karachi, Pakistan. She had a history of on and off pain at the epigastric region for past 8 months. Physical examination revealed no significant findings. Her laboratory findings were within normal limits. Abdominal ultrasonography showed multiple stones in the gallbladder with the largest one measuring 1.5 cm in size, normal wall of gall bladder. Common bile duct (CBD) and portal vein size are within normal limits. No anatomic variation was highlighted at ultrasound. A gallstone with occasional biliary colic was diagnosed, and the patient was planned for elective laparoscopic cholecystectomy. Perioperatively, dual cystic ducts were identified, clipped, and divided. It was found that the divided cystic duct contained two different channels. When the gallbladder was excised and examin ...

13 March 2016 in Scientifica
Verified
Journal Article
Open access
PDF file
VTVikash Talreja
Vikash Talreja
AAAun Ali
Aun Ali
SSSummaya Saeed
Summaya Saeed
KRKiran Rani
Kiran Rani
SSSunil Samnani
Sunil Samnani
MHMumtazuddin Haider
Mumtazuddin Haider
Background.There has been argument between clinical practitioners about clamping catheter or not prior to its removal after transurethral resection of prostate (TURP). We conducted a clinical trial to assess whether clamping has any role in early bladder tone recovery particularly in patients who undergo TURP.Methods.Randomized clinical trial was conducted at a tertiary care hospital, Karachi from January 2014 to July 2015. Eighty-six study participants who underwent TURP were randomly allocated into two groups of 43 participants each. In Group I, patient’s Foley catheter was not clamped prior to its removal and in Group II Foley catheter was clamped. Data of all subjects were analyzed using SPSS version 20.Results.There was no significant difference in age and weight of resected tissues between two groups. Among 4 patients in Group I who required recatheterization, 1 patient was discharged with catheter as compared to Group II in which 2 patients were discharged with catheter (P=0.99). Only 1 patient (2.3%) in Group II had bleeding which required recatheterization. Length of stay was significantly affected by early and free removal of Foley catheter (P<0.001).Conclusion.The results of current study identified that clamping whether done or not had no significant impact on urinary retention.

19 September 2024 in Endoscopy
Verified
Journal Article
Closed access
PDF file
ACAlessandra Ceccacci
Alessandra Ceccacci
MGMehul Gupta
Mehul Gupta
MEMaximilian Eisele
Maximilian Eisele
RKRishad Khan
Rishad Khan
JBJonathan Besney
Jonathan Besney
OGon behalf of the CReATE Working Group
on behalf of the CReATE Working Group
Background Post-endoscopic retrograde cholangiopancreatography (ERCP) adverse events (AEs) are common, as is unplanned healthcare utilization (UHU). We aimed to assess potential etiologic associations between intra-/post-procedural patient-reported experience measures (PREMs) and post-ERCP AEs and UHU. Methods Prospective data from a multicenter collaborative were used. A 0–10 Likert-based PREM assessing intra- and post-procedural symptoms was applied to patients following ERCP, and follow-up was performed at 30 days to identify AEs and UHU for reasons not meeting the definitions of any AE. Multivariable logistic regression was conducted using PREM domains as exposures and AEs and UHU as outcomes, with a priori selected covariates. Odds ratios (ORs) and 95 %CIs for each PREM domain were reported. Results From 2018 to 2023, 3434 patients were included. A post-procedural abdominal pain score > 3 was associated with pancreatitis (OR 3.71 [95 %CI 2.37–5.73]), while a score > 6 was associated with perforation (OR 9.54 [95 %CI 1.10–59.37]). Post-procedural pain was also associated with UHU within 30 days when used as a continuous exposure (OR 1.08 per point [95 %CI 1.01–1.16]), and when partitioned at a score > 3 (OR 1.79 [95 %CI 1.13–2.74]) and a score > 6 (OR 1.93 [95 %CI 1.02–3.46]). No other intra- or post-procedural PREMs were associated with any AEs or UHU. Conclusions Patient-reported abdominal pain from a Likert-based PREM at the time of discharge from ERCP was associated with pancreatitis, perforation, and UHU within 30 days. Applying PREMs could potentially prevent UHU and/or facilitate earlier management and improved outcomes for patients with post-ERCP AEs.

23 January 2025 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
ZSZachary L Smith
Zachary L Smith
AKAhmed Kayal
Ahmed Kayal
YRYibing Ruan
Yibing Ruan
BLBrendan Cord Lethebe
Brendan Cord Lethebe
PSPeter D Siersema
Peter D Siersema
SHSteven J Heitman
Steven J Heitman
Background and Aims: Endoscopic retrograde cholangiopancreatography (ERCP) is performed using anaesthesia or conscious sedation, though the effectiveness, adverse events (AEs), and tolerability of each approach remain unclear. Thus, we compared these approaches prospectively. Methods: We performed a multi-centre prospective cohort study including patients with native papillae undergoing ERCP for biliary indications between 2018 and 2023. The primary outcome was sedation-related AEs, defined as sustained hypoxaemia or hypotension, unplanned mask ventilation or intubation, vasopressor or reversal agent use, cardiorespiratory arrest, or death. Secondary outcomes included other AEs, technical success measures, and patient-reported tolerability using a validated scale. Multivariable logistic regression was performed in addition to propensity score-matched analyses. Results: At 8 centres, a total of 3174 first-time biliary ERCPs were performed, 433 (13.6%) employing anaesthesia. Nine sedation-related AEs occurred with conscious sedation (0.3%), while 2 (0.5%) occurred with anaesthesia (odds ratio, OR, 0.35, 0.07-2.37). Only 25 (0.9%) conscious sedation-supported ERCPs were aborted due to the inability to appropriately sedate patients. There were no significant differences in other AE rates, cannulation success, time, or attempts, use of pre-cut or needle-knife access methods, or inadvertent pancreatic duct cannulation. Odds of significant patient-reported intra-procedural awareness and discomfort were both higher with conscious sedation (ORs 16.19, 4.81-54.53, and 21.25, 4.44-101.61, respectively). Propensity score-matched analyses yielded no differences in any outcome compared with primary analyses. Conclusions: Routine biliary ERCP is equally safe and effective with conscious sedation (vs anaesthesia). Given regional resource limitations, conscious sedation is justified as a primary option for routine biliary ERCP.

13 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMillie Chau
Millie Chau
SSSunil Samnani
Sunil Samnani
FBFateh Bazerbachi
Fateh Bazerbachi
AMAnirudh Mirakhur
Anirudh Mirakhur
YRYibing Ruan
Yibing Ruan
NFNauzer Forbes
Nauzer Forbes
Background: Despite post-ERCP pancreatitis (PEP) being a major focus of outcomes research in endoscopic retrograde cholangiopancreatography (ERCP), little is known regarding the frequency with which asymptomatic biochemical and/or radiologic pancreatic alterations occur in patients following ERCP. Methods: Adult inpatients undergoing ERCP were identified from a prospective ERCP registry. Patients with any abdominal pain, confirmed PEP, or pancreatitis or abnormal pancreatic enzymes preceding ERCP were excluded. Primary outcomes were asymptomatic lipase elevation on bloodwork within 24 h of ERCP or asymptomatic cross-sectional imaging findings consistent with acute pancreatitis in the absence of clinical PEP within 14 days. Multinomial logistic regression and multiple logistic regression were used to examine associations between exposures and lipase levels and between PEP or imaging findings, respectively. Results: In total, 646 and 187 patients were analyzed as part of the biochemical and radiologic cohorts, respectively. A total of 26.0% of patients had asymptomatic elevations in lipase above the upper limit of normal (ULN) within 24 h, and 9.4% had elevations >3× ULN. A total of 20.9% of patients had incidental findings of enlargement, inflammation/edema/fat stranding, peri-pancreatic fluid collections, and/or necrosis on cross-sectional imaging within 14 days. Pancreatic contrast injection was associated with higher odds of asymptomatic lipasemia (adjusted odds ratio, AOR, 7.22; 95% confidence intervals, CI, 1.13 to 46.02), as was the use of the double-wire technique (AOR 15.74; 95% 1.15 to 214.74) and placement of a common bile duct stent (AOR 4.19; 95% CI 1.37 to 12.77). Over 10 cannulation attempts were associated with the presence of one or more radiologic finding(s) (AOR 33.95; 95% CI 1.64, to 704.13). Conclusions: Significant rates of incidental biochemical and/or radiologic pancreatic abnormalities are present following ERCP. Clinicians should be aware of our findings to minimize misclassification and better direct healthcare utilization.